Bet_Noire
Merus (NASDAQ:MRUS) has received accelerated FDA approval for its drug Bizengri for the treatment of NRG1+ cancers of the pancreas and lung.
The agency approved Bizengri, also known as zenocutuzumab-zbco, for the treatment of pancreatic adenocarcinoma or non–small cell lung cancer that
